Drug intelligence / Profile preview

orphenadrine citrate + aspirin + caffeine

Development stage
Approved
Lead developer
Galt Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

A **combination pharmaceutical** consisting of three active ingredients: **orphenadrine citrate**, **aspirin**, and **caffeine**. Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic and possible analgesic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) providing analgesic, antipyretic, and anti-inflammatory effects primarily via inhibition of cyclooxygenase; caffeine is a central nervous system stimulant that may enhance analgesic effects by antagonizing adenosine receptors. This drug combination is indicated for the symptomatic relief of mild to moderate pain associated with acute musculoskeletal disorders, used as an adjunct to rest and physical therapy[1][2][3][7][9][11].

Brand names
OrphengesicOrphengesic ForteNorgesicNorgesic Forte
Other names
orphenadrine citrate, aspirin, and caffeineorphenadrine/aspirin/caffeine
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)NMDAR (Glutamate receptor ionotropic, NMDA)mAChR (Muscarinic acetylcholine receptors)ADOR (Adenosine receptors)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on orphenadrine citrate + aspirin + caffeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on orphenadrine citrate + aspirin + caffeine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call